Abbott Laboratories (ABT)vsGlobus Medical (GMED)
ABT
Abbott Laboratories
$105.62
-2.21%
HEALTHCARE · Cap: $177.07B
GMED
Globus Medical
$80.26
-1.42%
HEALTHCARE · Cap: $10.45B
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 1402% more annual revenue ($46.59B vs $3.10B). GMED leads profitability with a 18.9% profit margin vs 11.7%. GMED appears more attractively valued with a PEG of 1.73. GMED earns a higher WallStSmart Score of 74/100 (B).
ABT
Buy52
out of 100
Grade: C-
GMED
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-46.2%
Fair Value
$73.35
Current Price
$105.62
$32.27 premium
Margin of Safety
+35.9%
Fair Value
$137.63
Current Price
$80.26
$57.37 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Earnings expanding 66.7% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 21.3%
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 47.5%
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap. Revenue growth of 13.0% demonstrates continued momentum.
Bull Case : GMED
The strongest argument for GMED centers on EPS Growth, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 18.9% and operating margin at 21.3%. Revenue growth of 27.0% demonstrates continued momentum.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.
Bear Case : GMED
The primary concerns for GMED are PEG Ratio.
Key Dynamics to Monitor
ABT profiles as a value stock while GMED is a growth play — different risk/reward profiles.
GMED carries more volatility with a beta of 0.95 — expect wider price swings.
GMED is growing revenue faster at 27.0% — sustainability is the question.
ABT generates stronger free cash flow (916M), providing more financial flexibility.
Bottom Line
GMED scores higher overall (74/100 vs 52/100), backed by strong 18.9% margins and 27.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Globus Medical
HEALTHCARE · MEDICAL DEVICES · USA
Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. The company is headquartered in Audubon, Pennsylvania.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?